IP Library Granted Patent US 10,434,065
Granted Patent B2
US 10,434,065 · App. 15/456,111 · Granted Oct 8, 2019

Microfluidic liposome synthesis, purification and active drug loading

Inventors: Renee Hood (Baltimore, MD); Donald Lad DeVoe (Bethesda, MD)
Assignee: University of Maryland, College Park
A61K9/1277A61K9/1278A61K31/00A61K31/5415A61K31/704A61K31/7048A61K31/7068B01J13/08B01J19/0093B01J2219/0086B01J2219/00894
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,434,065
App. No.
15/456,111
Granted
Oct 8, 2019
Kind
B2
Abstract

Microfluidic methods and systems are provided for continuous flow synthesis and active loading of liposomes, which include a liposome formation region configured to form a population of liposomes and a microdialysis region downstream from the liposome formation region and configured to form a transmembrane gradient for active drug loading of the liposomes. Microfluidic methods and systems for high throughput production of liposomes are also provided featuring high aspect ratio microchannels.

Claims (31)

1. A microfluidic device for synthesis of liposomes, comprising:

a sample flow channel;

a first inlet channel in fluid communication with said sample flow channel;

second and third inlet channels in fluid communication with said sample flow channel, said first, second and third inlet channels converging at a flow focusing region within said sample flow channel, wherein said sample flow channel has an aspect ratio (height:width) exceeding 20:1 at said flow focusing region;

a counterflow channel adjacent to said sample flow channel and downstream from said flow focusing region; and

a membrane in between said sample flow channel and said counterflow channel, said membrane configured to permit buffer exchange between said sample flow channel and said counterflow channel.

2. The microfluidic device of claim 1 , wherein said aspect ratio is 50:1 or greater.

3. The microfluidic device of claim 1 , wherein said aspect ratio is 100:1 or greater.

4. The microfluidic device of claim 1 , wherein said first, second and third inlet channels are vertically oriented relative to each other.

5. The microfluidic device of claim 1 , wherein said membrane is configured to prevent selected particles from passing between said sample flow channel and said counterflow channel.

6. The microfluidic device of claim 1 , further comprising a fourth inlet channel in fluid communication with said sample flow channel, said fourth inlet channel configured to direct a first agent into said sample flow channel.

7. The microfluidic device of claim 6 , wherein said fourth inlet channel converges with said sample flow channel at said flow focusing region.

8. The microfluidic device of claim 6 , wherein said fourth inlet channel converges with said sample flow channel downstream of said flow focusing region.

9. The microfluidic device of claim 7 , further comprising a fifth inlet channel in fluid communication with said sample flow channel, said fifth inlet channel configured to direct a second agent into said sample flow channel.

10. The microfluidic device of claim 9 , wherein said fifth inlet channel converges with said sample flow channel downstream of said flow focusing region.

11. The microfluidic device of claim 1 , further comprising a lipid solution flowing through said first inlet channel and into said sample flow channel, and a buffer solution flowing through said second and third inlet channels and into said sample flow channel, wherein said lipid solution and said buffer solution interact at said flow focusing region and form a population of liposomes.

12. The microfluidic device of claim 11 , wherein said population of liposomes have a median diameter of between about 20 nm and about 500 nm.

13. The microfluidic device of claim 12 , wherein said population of liposomes have a median diameter of between about 20 nm and about 100 nm.

14. The microfluidic device of claim 11 , wherein said population of liposomes have a percent polydispersity of less than about 10%.

15. The microfluidic device of claim 14 , wherein said population of liposomes have a percent polydispersity of less than about 5%.

16. A microfluidic device for synthesis of liposomes, comprising:

a sample flow channel;

a first inlet channel in fluid communication with said sample flow channel;

second and third inlet channels in fluid communication with said sample flow channel, said first, second and third inlet channels converging at a flow focusing region within said sample flow channel, wherein said sample flow channel has an aspect ratio (height:width) exceeding 20:1 at said flow focusing region;

a lipid solution flowing through said first inlet channel and into said sample flow channel, and a buffer solution flowing through said second and third inlet channels and into said sample flow channel, wherein said lipid solution and said buffer solution interact at said flow focusing region and form a population of liposomes;

a counterflow channel adjacent to said sample flow channel and downstream from said flow focusing region; and

a membrane in between said sample flow channel and said counterflow channel, said membrane permitting buffer exchange between said sample flow channel and said counterflow channel and establishing a transmembrane ion gradient in said population of liposomes.

17. The microfluidic device of claim 16 , further comprising a fourth inlet channel throughout which a first agent flows and in fluid communication with said sample flow channel, said fourth inlet channel downstream of said counterflow channel, wherein said first agent is actively loaded within intravesicular spaces of said liposomes to form agent-loaded liposomes.

18. The microfluidic device of claim 17 , wherein said first agent is a therapeutic or diagnostic agent.

19. The microfluidic device of claim 18 , wherein said agent-loaded liposomes exhibit a drug-to-lipid molar ratio of greater than 0.5.

20. The microfluidic device of claim 19 , wherein said agent-loaded liposomes exhibit a drug-to-lipid molar ratio of greater than 2.0.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2019
From: DEVOE, DONALD LAD; HOOD, RENEE
To: UNIVERSITY OF MARYLAND, COLLEGE PARK
Reel/Frame 050134/0449 →
Continuity (3)
Division 14524797 · Oct 27, 2014
Provisional Application 61896204 · Oct 28, 2013
Related Publication 20170181972A1 · Jun 29, 2017